<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-166779</identifier>
<setSpec>1131-3587</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Antithrombotic treatment in high-risk situations. Case reports</dc:title>
<dc:description xml:lang="en">The great variety of antithrombotic drugs available combined with the absence of a consensus on the best regimen for any particular patient means that the list of therapies to choose from is long. Before carrying out a percutaneous coronary intervention (when necessary), it is essential to take many important factors into consideration in addition to the risk of a recurrent ischemic event: for example, the risk of bleeding, the dose of clopidogrel or low-molecular-weight heparin administered and its timing, the patient&#146;s renal function, and whether the patient has a history of adverse reactions to drugs, such as heparin induced thrombocytopenia. The aim of these two case reports was to highlight the steps that should be taken at the point when a particular form of antithrombotic treatment is started (AU)</dc:description>
<dc:creator>Lacunza, Javier</dc:creator>
<dc:creator>Valdés, Mariano</dc:creator>
<dc:creator>Marín, Francisco</dc:creator>
<dc:creator>López Cuenca, Ángel</dc:creator>
<dc:creator>Muñoz Esparza, Carmen</dc:creator>
<dc:creator>Pinar, Eduardo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">La combinación de una gran variedad de fármacos antitrombóticos disponibles y la falta de consenso sobre el régimen óptimo para un paciente determinado han dado lugar a una larga lista de posibilidades. Además del riesgo de eventos isquémicos recurrentes, existen otros factores importantes que se debe tener en cuenta antes del intervencionismo coronario percutáneo (en caso de que sea necesario), como el riesgo de sangrado, el momento y la dosis de clopidogrel o heparina de bajo peso molecular, la función renal o si el paciente tiene historia de reacciones adversas a fármacos, como trombocitopenia inducida por heparina. Se presentan dos casos clínicos con la intención de subrayar las medidas que se debe considerar al iniciar un tratamiento antitrombótico determinado (AU)</dc:description>
<dc:source>Rev. esp. cardiol. Supl. (Ed. impresa);10(supl.D): 59d-65d, 2010. ilus, tab</dc:source>
<dc:identifier>ibc-166779</dc:identifier>
<dc:title xml:lang="es">Tratamiento antitrombótico en situaciones de alto riesgo. Casos clínicos</dc:title>
<dc:subject>^d331</dc:subject>
<dc:subject>^d1287^s22012</dc:subject>
<dc:subject>^d33105</dc:subject>
<dc:subject>^d24519^s22074</dc:subject>
<dc:subject>^d5478^s22073</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d52613^s22057</dc:subject>
<dc:subject>^d19059</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d55037^s22074</dc:subject>
<dc:subject>^d1831^s22074</dc:subject>
<dc:type>article</dc:type>
<dc:date>201000</dc:date>
</metadata>
</record>
</ibecs-document>
